Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer

Autor: Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF

Publikováno v: OncoTargets and Therapy, Vol Volume 14, Pp 1873-1882 (2021)

Poshita-Kumari Seesaha,1,* Kang-Xin Wang,2,* Guo-Qun Wang,2 Ting-Yun Cui,2 Feng-Jiao Zhao,1 Lan-Lan Pan,1 Xiang-Cheng Li,3 Yong-Qian Shu,1 Xiao-Feng Chen1,2 1Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanji

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::55f4bc668b6315f735489b76659ba2fb
https://www.dovepress.com/current-progress-and-future-perspectives-of-immune-checkpoint-inhibito-peer-reviewed-article-OTT

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.

Autor: Chen X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Wu X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Wu H; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Gu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Shao Y; Medical Department, Nanjing Geneseeq Technology Inc, Nanjing, China., Shao Q; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhu F; Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Li X; Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Qian X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Hu J; Department of Oncology, Nanjing Red Cross Hospital, Nanjing, China., Zhao F; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Mao W; Department of Oncology, Jiangyin People's Hospital, Jiangyin, China., Sun J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Wang J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Han G; Department of Oncology, Taizhou People's Hospital Affiliated to Nantong University, Taizhou, China., Li C; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Xia Y; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Seesaha PK; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhu D; Medical Department, Nanjing Geneseeq Technology Inc, Nanjing, China., Li H; Medical Department, Jiangsu Hengrui Medicine Co Ltd, Lianyungang, China., Zhang J; Medical Department, 3D Medicines Inc, Shanghai, China., Wang G; Medical Department, Burning Rock Biotech, Guangzhou, China., Wang X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Li X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China shuyongqian@csco.org.cn.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Nov; Vol. 8 (2).

The interplay between dietary factors, gut microbiome and colorectal cancer: a new era of colorectal cancer prevention.

Autor: Seesaha PK; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Chen X; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Wu X; Hepatobiliary Center, The First Affiliated Hospital, Nanjing Medical University, Jiangsu, PR China., Xu H; Department of Nutrition, Third Military Medical University Daping Hospital & Research Institute of Surgery, Chongqing 400042, Sichuan, PR China., Li C; Hepatobiliary Center, The First Affiliated Hospital, Nanjing Medical University, Jiangsu, PR China., Jheengut Y; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Zhao F; Oncology Department, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China., Liu L; School of Public Health, Guizhou Medical University, Guiyang, PR China., Zhang D; Department of General Surgery, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, PR China.

Publikováno v: Future oncology (London, England) [Future Oncol] 2020 Mar; Vol. 16 (7), pp. 293-306. Date of Electronic Publication: 2020 Feb 18.